Your session is about to expire
← Back to Search
Prostacyclin Analogue
Iloprost in Gas Exchange/Pulm Mechanics in Chronic Obstructive Pulmonary Disease (COPD) (Iloprost Trial)
N/A
Waitlist Available
Led By Gary T Kinasewitz, MD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Approved for 5 Other Conditions
All Individual Drugs Already Approved
No Placebo-Only Group
Summary
The investigators believe that iloprost will improve gas exchange in COPD patients with pulmonary hypertension.
Eligible Conditions
- Chronic Obstructive Pulmonary Disease
- Pulmonary Hypertension
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment2 Interventions
This study will examine the hypothesis that iloprost maintains and improves ventilation perfusion matching in patients with COPD as reflected by 1) a constant or reduced alveolar to arterial O2 difference as calculated from the measured arterial blood gases obtained before and after iloprost administration, 2) an improvement in the lung diffusing capacity for carbon monoxide that occurs in the absence of a change in spirometry, 3) an improvement in the ventilatory equivalent for oxygen and CO2 measured by expired gas analysis.
It is anticipated that a positive result in this pilot study would lead to a larger long-term study examining the effect of iloprost on gas exchange, exercise tolerance and quality of life in patients with COPD.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Iloprost
FDA approved
Iloprost
FDA approved
Find a Location
Who is running the clinical trial?
University of OklahomaLead Sponsor
474 Previous Clinical Trials
93,675 Total Patients Enrolled
Gary T Kinasewitz, MDPrincipal InvestigatorUniversity of Oklahoma
3 Previous Clinical Trials
540 Total Patients Enrolled